Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on March 18, 2013. The filing serves as a Regulation FD disclosure regarding an Investor Day presentation delivered to analysts and investors in New York, New York. The presentation included management's projections for future revenue, adjusted operating margin, adjusted operating cash flows, and adjusted net income and EPS.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references an attached presentation (Exhibit 99.1) containing these projections. The document defines the company's "adjusted" non-GAAP financial measures, which exclude:
- Acquisition-related charges and facility consolidation/optimization costs.
- Asset write-downs, disposition charges, and severance charges.
- Litigation charges/gains and non-cash interest expense impacts from convertible debt.
- Unusual items, specific R&D expenditures (e.g., design verification testing for neuromodulation), and gains/losses on investment sales.
- Tax impacts related to the above adjustments and the consolidation of the Swiss Orthopaedic facility.
Material Changes
The filing does not report specific historical financial changes or variances compared to prior periods. It notes that a reconciliation of the non-GAAP measures to GAAP results is available in the Company's 2012 Form 10-K filed on February 27, 2013.
Guidance, Outlook, and Risks
Guidance and Outlook: Management provided forward-looking statements regarding future sales, expenses, profitability, business growth, and capital expenditures. These projections are based on current expectations and are subject to significant uncertainty.
Risks and Contingencies: The filing lists numerous factors that could cause actual results to differ materially from projections, including:
- Dependence on a limited number of customers and customer ordering patterns.
- Pricing pressure, product obsolescence, and inability to market products.
- Reliance on third-party suppliers and challenges in maintaining quality standards.
- Intellectual property challenges, product liability claims, and regulatory changes in the healthcare industry.
- Global economic factors, including currency exchange rates and interest rates.
- Risks associated with acquisitions, integration, and expansion into new markets.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached presentation) for specific numerical projections on revenue, margins, and cash flow.
- Consult the 2012 Form 10-K (filed Feb 27, 2013) for the reconciliation of non-GAAP measures to GAAP results.
- Verify the status of the Swiss Orthopaedic facility consolidation and associated tax charges.
- Assess the progress of the neuromodulation platform development and related R&D expenditures.
- Monitor customer concentration risks and any changes in ordering patterns.